Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xianjun Yu

Showing results (411-420 of 421) with videos related to

Pageof 43
Sort By:
JAMA Surgery|October 25, 2023
Short-Term Outcomes Following Laparoscopic vs Open Pancreaticoduodenectomy in Patients With Pancreatic Ductal Adenocarcinoma: A Randomized Clinical TrialMin Wang, Shutao Pan, Tingting Qin, et al.
The Lancet. Oncology|September 23, 2020
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 studyJianming Xu, Lin Shen, Zhiwei Zhou, et al.
Neuroendocrinology|July 11, 2018
Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine TumoursEric Raymond, Matthew H Kulke, Shukui Qin, et al.
Hepatobiliary Surgery and Nutrition|August 25, 2020
International expert consensus on laparoscopic pancreaticoduodenectomyRenyi Qin, Michael L Kendrick, Christopher L Wolfgang, et al.
Carcinogenesis|January 10, 2013
Identification of common variants in BRCA2 and MAP2K4 for susceptibility to sporadic pancreatic cancerLiming Huang, Chen Wu, Dianke Yu, et al.
Nature Genetics|December 14, 2011
Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populationsChen Wu, Xiaoping Miao, Liming Huang, et al.
Nature Medicine|July 16, 2025
CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trialJia Liu, Jianwei Yang, Yuping Sun, et al.
Cell|January 18, 2025
Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patientsLiping Zhong, Lu Gan, Bing Wang, et al.
Cancer Cell|April 4, 2025
Proteogenomic characterization of non-functional pancreatic neuroendocrine tumors unravels clinically relevant subgroupsShunrong Ji, Lihua Cao, Jing Gao, et al.
International Journal of Oncology|December 31, 2016
Surgery management for sporadic small (≤2 cm), non-functioning pancreatic neuroendocrine tumors: a consensus statement by the Chinese Study Group for Neuroendocrine Tumors (CSNET)Guang Yang, Meng Ji, Jie Chen, et al.
Pageof 43

Showing results (411-420 of 421) with videos related to

Sort By:
Pageof 43
JAMA Surgery|October 25, 2023
Short-Term Outcomes Following Laparoscopic vs Open Pancreaticoduodenectomy in Patients With Pancreatic Ductal Adenocarcinoma: A Randomized Clinical TrialMin Wang, Shutao Pan, Tingting Qin, et al.
The Lancet. Oncology|September 23, 2020
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 studyJianming Xu, Lin Shen, Zhiwei Zhou, et al.
Neuroendocrinology|July 11, 2018
Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine TumoursEric Raymond, Matthew H Kulke, Shukui Qin, et al.
Hepatobiliary Surgery and Nutrition|August 25, 2020
International expert consensus on laparoscopic pancreaticoduodenectomyRenyi Qin, Michael L Kendrick, Christopher L Wolfgang, et al.
Carcinogenesis|January 10, 2013
Identification of common variants in BRCA2 and MAP2K4 for susceptibility to sporadic pancreatic cancerLiming Huang, Chen Wu, Dianke Yu, et al.
Nature Genetics|December 14, 2011
Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populationsChen Wu, Xiaoping Miao, Liming Huang, et al.
Nature Medicine|July 16, 2025
CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trialJia Liu, Jianwei Yang, Yuping Sun, et al.
Cell|January 18, 2025
Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patientsLiping Zhong, Lu Gan, Bing Wang, et al.
Cancer Cell|April 4, 2025
Proteogenomic characterization of non-functional pancreatic neuroendocrine tumors unravels clinically relevant subgroupsShunrong Ji, Lihua Cao, Jing Gao, et al.
International Journal of Oncology|December 31, 2016
Surgery management for sporadic small (≤2 cm), non-functioning pancreatic neuroendocrine tumors: a consensus statement by the Chinese Study Group for Neuroendocrine Tumors (CSNET)Guang Yang, Meng Ji, Jie Chen, et al.
Pageof 43